- Email: [email protected]
5604186 Encapsulated enzyme breaker and method for use in treating subterranean formations
PATENT ABSTRACTS
5602021 METHOD FOR GENERATING PROTEOLYTIC ENZYMES •S P E C I F I C A G A I N S T A SELECTED PEPTIDE SEQUENCE Davis Claude G; Guay Gordon G Foster City, CA, UNITED STATES Assigned to Catalytic Antibodies Inc The present invention describes methods for screening or selecting novel proteolytic enzymes. These enzymatic functions can be selected from isolated chromosomal DNA libraries or from pools of mutagenized DNA encoding a proteolytic function, in particular, the selection method of the present invention, a phage gene is chosen that encodes a gene product necessary for the production of a phage. The phage carrying the modified gene is introduced into a host. Also, DNA libraries present within a cloning vector are introduced into host cells. The host cells are grown under conditions where the introduced libraries are expressed in the host cells. The presence of an enzymatic function capable of cleaving the target peptide is identified on the basis of production of infective phage.
5603956 CROSS-LINKED ENZYMATICALLY CONTROLLED DRUG RELEASE Mateescu Mircea A; Dumoulin Yves; Cartilier Louis; Lenaerts Vincen Verdun, CANADA Assigned to Labopharm Inc The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, alpha-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the alpha-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of alpha-amylase in the tablet. The
759
amount of alpha-amylase is defined in terms of Enzyme Units.
5604186 ENCAPSULATED ENZYME BREAKER AND METHOD FOR USE IN TREATING SUBTERRANEAN FORMATIONS Hunt Charles V; Powell Ronald J; Carter Michael L; Pelley Samuel D; Norman Lewis R Duncan, OK, UNITED STATES Assigned to Halliburton Company The present invention relates to a method of preparing an encapsulated enzyme breaker and method of use in treating a subterranean formation. An encapsulated breaker is prepared by coating an enzyme on a cellulose substrate. A micron-sized particulate is admixed with the enzyme solution to prevent undesired agglomeration of the substrate. The enzyme solution coated substrate is covered with a membrane comprising a partially hydrolyzed acrylic crosslinked with either an aziridine prepolymer or a carbodiimide. The membrane contains imperfections through which an aqueous fluid may pass into the breaker to contact the enzyme and diffuse the enzyme outward from the breaker particle.
5604190 STABLE LIQUID ENZYME COMPOSITIONS AND METHODS OF USE IN CONTACT LENS CLEANING AND DISINFECTING SYSTEMS Chowhan Masood A; Quintana Ronald P; Asgharian Bahra; Hong Bor-Shyue; Bilbault Thierr; Rosenthal Ruth A Arlington, TX, UNITED STATES Assigned to Alcon Laboratories Inc Compositions containing a stable, liquid, ophthalmicaUy acceptable enzyme and methods involving the combined use of these compositions with a polymeric antimicrobial agent, and
5602021 METHOD FOR GENERATING PROTEOLYTIC ENZYMES •S P E C I F I C A G A I N S T A SELECTED PEPTIDE SEQUENCE Davis Claude G; Guay Gordon G Foster City, CA, UNITED STATES Assigned to Catalytic Antibodies Inc The present invention describes methods for screening or selecting novel proteolytic enzymes. These enzymatic functions can be selected from isolated chromosomal DNA libraries or from pools of mutagenized DNA encoding a proteolytic function, in particular, the selection method of the present invention, a phage gene is chosen that encodes a gene product necessary for the production of a phage. The phage carrying the modified gene is introduced into a host. Also, DNA libraries present within a cloning vector are introduced into host cells. The host cells are grown under conditions where the introduced libraries are expressed in the host cells. The presence of an enzymatic function capable of cleaving the target peptide is identified on the basis of production of infective phage.
5603956 CROSS-LINKED ENZYMATICALLY CONTROLLED DRUG RELEASE Mateescu Mircea A; Dumoulin Yves; Cartilier Louis; Lenaerts Vincen Verdun, CANADA Assigned to Labopharm Inc The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, alpha-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the alpha-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of alpha-amylase in the tablet. The
759
amount of alpha-amylase is defined in terms of Enzyme Units.
5604186 ENCAPSULATED ENZYME BREAKER AND METHOD FOR USE IN TREATING SUBTERRANEAN FORMATIONS Hunt Charles V; Powell Ronald J; Carter Michael L; Pelley Samuel D; Norman Lewis R Duncan, OK, UNITED STATES Assigned to Halliburton Company The present invention relates to a method of preparing an encapsulated enzyme breaker and method of use in treating a subterranean formation. An encapsulated breaker is prepared by coating an enzyme on a cellulose substrate. A micron-sized particulate is admixed with the enzyme solution to prevent undesired agglomeration of the substrate. The enzyme solution coated substrate is covered with a membrane comprising a partially hydrolyzed acrylic crosslinked with either an aziridine prepolymer or a carbodiimide. The membrane contains imperfections through which an aqueous fluid may pass into the breaker to contact the enzyme and diffuse the enzyme outward from the breaker particle.
5604190 STABLE LIQUID ENZYME COMPOSITIONS AND METHODS OF USE IN CONTACT LENS CLEANING AND DISINFECTING SYSTEMS Chowhan Masood A; Quintana Ronald P; Asgharian Bahra; Hong Bor-Shyue; Bilbault Thierr; Rosenthal Ruth A Arlington, TX, UNITED STATES Assigned to Alcon Laboratories Inc Compositions containing a stable, liquid, ophthalmicaUy acceptable enzyme and methods involving the combined use of these compositions with a polymeric antimicrobial agent, and